Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Safety and PK Study of EDP-323
NCT05587478Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EDP-323 in respiratory syncytial virus infection (RSV) (3 arms), sponsored by Enanta Pharmaceuticals. Primary endpoint: Safety measured by adverse events up to 14 Days. Started Sep 2022; status: completed.
02
Drugs
EDP-323
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05587478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05587478.